- Stocks
- Pharma & Healthcare
- Indraprastha
Indraprastha share price
NSE: IGLPharma & HealthcareUtilities - Regulated Gas
Indraprastha at a glance
Indraprastha (NSE: IGL) closed at ₹141.87 on 22 Oct 2026, down 0.11% on the day. With a market capitalisation of ₹19,862 Cr, it ranks 357th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Utilities - Regulated Gas.
At its last close the stock traded at 12.8× trailing earnings, against a return on equity of 27.0% in FY25. Over the past year the share price has fallen 33.1%. Its 52-week range is ₹139.20 (29 Sep 2026) to ₹219.10 (4 Nov 2025); the last close is 35.2% below the high. Promoters held 45.00% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹19,862 CrRank 357 on NSE
- P/E (trailing)
- 12.8×
- Price to book
- 5.93×FY25
- ROE
- 27.0%FY25
- ROCE
- 33.1%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 11.9%FY25
- Book value / share
- ₹65.09FY25
- Dividend payout
- 25.6%FY25
- 52-week high
- ₹219.104 Nov 2025
- 52-week low
- ₹139.2029 Sep 2026
- 1-year return
- −33.1%
- RSI (14-day)
- 42.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.11% | −1.8% | −4.7% | −6.2% | −33.1% |
Indraprastha financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹831 Cr | ₹613 Cr | ₹888 Cr | ₹1,099 Cr | ₹1,245 Cr | ₹1,356 Cr |
| Operating profit | ₹48 Cr | ₹4 Cr | ₹79 Cr | ₹117 Cr | ₹166 Cr | ₹216 Cr |
| Net profit | ₹44 Cr | ₹2 Cr | ₹59 Cr | ₹86 Cr | ₹124 Cr | ₹161 Cr |
| EPS (₹) | ₹4.76 | ₹0.25 | ₹6.39 | ₹9.40 | ₹13.52 | ₹17.56 |
| Cash from operations | ₹86 Cr | ₹28 Cr | ₹71 Cr | ₹144 Cr | ₹200 Cr | ₹157 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹268 Cr | ₹273 Cr | ₹325 Cr | ₹379 Cr | ₹478 Cr | ₹597 Cr |
Indraprastha shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 45.00% | 45.00% | 45.00% | 45.00% | 45.00% | 45.00% |
| Foreign institutions | 14.67% | 16.82% | 17.21% | 16.99% | 17.08% | 10.16% |
| Domestic institutions | 26.18% | 23.99% | 24.08% | 24.18% | 23.26% | 30.03% |
| Non-institutions | 9.15% | 9.19% | 8.72% | 8.83% | 9.66% | 9.81% |
Indraprastha vs peers
The listed Pharma & Healthcare companies nearest to Indraprastha by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| PGHHProcter Gamble | ₹6,856.00 | −0.36% | −51.5% | ₹22,255 Cr | 26 | — |
| PIRPHYTOPiramal Phytoca | — | — | — | ₹21,083 Cr | — | — |
| SAGILITYSAGILITY | ₹44.78 | +1.08% | +0.9% | ₹20,963 Cr | 22.6 | — |
| GRANULESGranules India | ₹807.65 | +0.04% | +41.9% | ₹20,013 Cr | 33 | — |
| IGLIndraprastha | ₹141.87 | −0.11% | −33.1% | ₹19,862 Cr | 12.8 | — |
| COHANCECohance Lifesciences | ₹460.30 | −0.25% | −46.9% | ₹17,610 Cr | 98.6 | — |
| SHILPAMEDShilpa Medicare | ₹880.90 | +4.74% | +150.3% | ₹17,229 Cr | 70.9 | — |
Ask anything about Indraprastha
Pivot answers on the live chart with evidence you can check, and tests strategies against IGL's own history. Try: “Why has IGL moved over the last three months?” · “Backtest a 50-day moving-average crossover on IGL over five years” · “Compare IGL with PGHH on margins and valuation”
Frequently asked questions about Indraprastha
What is the share price of Indraprastha today?
Indraprastha (NSE: IGL) last closed at ₹141.87 on 22 Oct 2026. Its 52-week high is ₹219.10 and its 52-week low is ₹139.20.
What is the market cap of Indraprastha?
Indraprastha's market capitalisation is ₹19,862 Cr (₹19,862 Cr) at the 22 Oct 2026 close, ranking 357th among the NSE companies Pivot tracks.
What is the P/E ratio of Indraprastha?
Indraprastha trades at a trailing P/E of 12.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 33.
What is the ROE and ROCE of Indraprastha?
Return on equity was 27.0% in FY25 and return on capital employed was 33.1% in FY25 (standalone figures).
Is Indraprastha a debt-free company?
Indraprastha is close to debt-free: its debt-to-equity ratio was 0 in FY25.
How has Indraprastha stock performed over the last year?
Indraprastha's share price has fallen 33.1% over the past year, −6.2% over three months and −4.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Indraprastha?
As of 30 Jun 2026: promoters 45.00%, foreign institutions 10.16%, domestic institutions 30.03%, non-institutions 9.81%.
Who are Indraprastha's competitors?
The listed Pharma & Healthcare companies closest to Indraprastha by market cap are Procter Gamble, Piramal Phytoca, SAGILITY, Granules India, Cohance Lifesciences and Shilpa Medicare.
Is Indraprastha a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Indraprastha's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on IGL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with I · all NSE stocks · this page as text